No Data
Shanghai Xuerong Biotechnology Co.,Ltd.'s (SZSE:300511) Shares Bounce 64% But Its Business Still Trails The Industry
Shanghai Xuerong Bio-Technology changes ownership, new actual controller sets a "hundred billion Market Cap" flag | Quick read announcement.
① The control of Shanghai Xuerong Bio-Technology has changed, with chairman Yang Yongping relinquishing the position of the company's controlling Shareholder and actual controller. ② Jiang Zhi, an entrepreneur from the Online Games industry, will become the new actual controller. He stated that he hopes to build Shanghai Xuerong Bio-Technology into a publicly traded company with a revenue of 10 billion and a Market Cap of 100 billion in the next 3 to 5 years.
Shanghai Xuerong Bio-Technology (300511.SZ): plans to raise no more than 0.577 billion yuan through a private placement to Wanzihong.
On March 12, Glonghui reported that Shanghai Xuerong Bio-Technology (300511.SZ) announced a plan to issue Stocks to specific objects for the year 2025. The quantity of Stocks issued to specific objects will not exceed 30% of the company's total share capital before the issuance. Based on the company's total share capital and the number of outstanding Xuerong convertible bonds as of December 31, 2024, assuming that the Xuerong convertible bonds have not been converted into shares prior to this issuance, the number of Stocks issued to specific objects will not exceed 149,645,903 shares (including this number); if all Xuerong convertible bonds have been converted into shares prior to this issuance, the number of shares issued will not exceed 192,365,793 shares.
Shanghai Xuerong Bio-Technology (300511.SZ): Planning for a change in company control. Stocks are suspended.
On March 5, Gelonghui丨Shanghai Xuerong Bio-Technology (300511.SZ) announced that on March 5, 2025, it received notification from its controlling shareholder and actual controller, Mr. Yang Yongping, that he is planning a change in the company's control. It is expected that after the completion of this trade, the counterparty will obtain voting rights corresponding to 25.33% of the company's total equity, with the counterparty being a private enterprise in the technology service industry. Currently, all parties are verifying and negotiating specific transaction plans and agreements, with specific details to be subject to the relevant agreements signed by the parties. This transaction requires prior approval from the relevant departments.
Shanghai Xuerong Bio-Technology (300511.SZ) has issued a profit warning, estimating an annual net loss of between 0.435 billion yuan and 0.65 billion yuan.
Shanghai Xuerong Bio-Technology (300511.SZ) disclosed its performance forecast for 2024, expecting to belong to the listed company's Shareholders...
Xuerong Biology: Shanghai Xuerong Biotechnology Co., Ltd. 2024 Annual Performance Forecast
Revenues Working Against Shanghai Xuerong Biotechnology Co.,Ltd.'s (SZSE:300511) Share Price Following 26% Dive
